Pharma Journalist -

Takeda announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCRC) who…
Read More...

The three-day agenda for the 6th Chronic Kidney Disease (CKD) Drug development Summit has been announced. Taking place March 19-21, 2024 in Boston, M.A., this year’s program features…
Read More...

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and Nephron Pharmaceuticals, Inc. (Nephron), a leading manufacturer of sterile injectable drugs announced the…
Read More...

Landmark Bio, a collective endeavor bringing together leaders in industry, academia, and research hospitals to accelerate development and industrialization of next-generation genomic…
Read More...

AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in…
Read More...

Aldeyra Therapeutics, Inc., a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, announced that it has entered…
Read More...

Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies, announced the closing of a CHF25 million Series C financing led by Pureos…
Read More...

Prelude Therapeutics Incorporated and AbCellera announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for…
Read More...

Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded three clinical oncology…
Read More...

I-Mab, a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel…
Read More...